الفهرس 
Anatomy Of The The CorneaOnly 14 pages are availabe for public view
 |  | from | 96 |  |  |
| | | from | 96 | | |
Abstract
Corneal diseases are the leading cause of blindness worldwide, second only to cataract. While corneal transplantation is highly successful in restoring sight, severely diseased eyes with deep corneal vascularization, limbal stem cell deficiency (LSCD), autoimmune diseases and chemical injury etc. are prone to graft rejection. Keratoprosthesis (KPro) seems to offer visual rehabilitation in such situations where corneal transplantation has an extremely poor prognosis.
Keratoprosthesis, an artificial cornea, was developed to treat patients whose corneas are at high risk for immunological rejection after PK, or corneas with factors that might predispose them to graft failure after a failed PK.
This study was to evaluate Outcome of Boston type 1 Keratoprosthesis implantation in end-stage Corneal Diseases.
This study was performed on 10 eyes with end-stage Corneal Diseases implanted with Boston type 1 Kpro and examined at 1week, 1 month, 3 and 6 months after surgery to assess improvement in BCVA and incidence of complications.
BCVA was significantly improved at the last follow up (P=0.018).
Complication occuers in only 20% of cases in the form of Keratitis (stromal infiltration) TTT with fortified E.D in 10% of cases and Peripheral corneal melting TTT with scleral patch graft in 10% of cases.
ALL of the 10 Kpros were retained at the last follow-up retention rate 100%.
These results were compared with the previous studies of Boston Kpro as regard visual outcome, retention of the device and incidence of complication.
This showed that Boston keratoprosthesis provides improved vision and improved quality of life for patients suffering from corneal blindness due to end stage corneal diseases, however The trend of decrease in the BCVA over a period of time warrants long-term studies to monitor the late onset complications in the postoperative period.